Top Markets
#1 MowCat MowCat +48.96%
#2 Audiera Audiera +28.09%
#3 Velvet Velvet +27.19%
#4 Bermuda Shorts Bermuda Shorts +24.66%
#5 Biconomy Biconomy +22.49%
#6 aPriori aPriori +22.35%
#7 Quack AI Quack AI +21.37%
#8 Derive Derive +19.47%
#9 SkyAI SkyAI +14.21%
#10 Geodnet Geodnet +12.98%
Coin of the day
MowCat MowCat
設定
言語
日本
通貨
USD
テーマ
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
株式のランク #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
株価
$2.70
最終同期: 2023-05-17
時価総額
$4.13M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Graybug Vision, Inc. (GRAY)

カテゴリー

Healthcare
Graybug Vision, Inc.（GRAY）の利益
2026 時点の利益 TTM: 0
Graybug Vision, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Graybug Vision, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE